Federal hemp/cannabinoid policy: The Trump administration says it’s ready to work with Congress to keep hemp-derived cannabinoid products legal, as a federal agriculture bill heads through lawmakers and could tighten what’s allowed at retail. Rescheduling ripple effects: A DOJ decision to move medical cannabis from Schedule I to Schedule III is already changing the business math for operators and research, even as recreational cannabis stays stuck under federal rules. TSA travel confusion: TSA quietly updated its guidance language, removing “marijuana” from a key line while still listing medical marijuana as allowed with special instructions—so travelers should not assume anything has changed. Road safety rules: NSW is moving toward a “three strikes” approach for drivers with medicinal cannabis in their system, aiming to balance access with enforcement. State regulation fights: Pennsylvania’s Senate rejected a bill to create a Cannabis Control Board and crack down on intoxicating hemp THC products, while North Carolina lawmakers push for an age limit on hemp-based products. Industry & access: Trulieve is set to become the first U.S. cannabis company listed on the NYSE after federal rescheduling opened a pathway for medical operators. Local enforcement: Carpinteria cannabis growers are scrambling to install odor-control tech to avoid license revocations. Public health & safety: Europe’s drug report warns of more potent substances and vapes being used to deliver harmful compounds, raising new risks for consumers. CBD in the spotlight (and controversy): A Venice inquest heard a man smoked CBD before drowning, underscoring how CBD use can still show up in real-world safety stories.